{"id":"neoral-cyclosporine","safety":{"commonSideEffects":[{"rate":"25-50","effect":"Nephrotoxicity/renal dysfunction"},{"rate":"25-50","effect":"Hypertension"},{"rate":"10-25","effect":"Tremor"},{"rate":"10-25","effect":"Gingival hyperplasia"},{"rate":"10-25","effect":"Hirsutism"},{"rate":"10-20","effect":"Headache"},{"rate":"10-20","effect":"Hyperkalemia"},{"rate":"15-30","effect":"Infections"},{"rate":"1-5","effect":"Neurotoxicity (encephalopathy)"},{"rate":"5-10","effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cyclosporine forms a complex with the intracellular protein cyclophilin, which then inhibits the phosphatase calcineurin. This prevents dephosphorylation and nuclear translocation of NFAT (nuclear factor of activated T cells), thereby suppressing the transcription of IL-2 and other pro-inflammatory cytokines essential for T-cell proliferation and activation. The result is selective immunosuppression without affecting B-cell or antibody production directly.","oneSentence":"Cyclosporine inhibits T-cell activation by binding to cyclophilin and blocking calcineurin-mediated transcription of interleukin-2 and other cytokines.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:38:36.980Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas)"},{"name":"Severe active rheumatoid arthritis"},{"name":"Severe psoriasis"},{"name":"Nephrotic syndrome (minimal change disease)"},{"name":"Severe atopic dermatitis"},{"name":"Uveitis"}]},"trialDetails":[{"nctId":"NCT07224529","phase":"PHASE4","title":"Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-04-01","conditions":"Meibomian Gland Dysfunction (MGD)","enrollment":48},{"nctId":"NCT07463950","phase":"PHASE4","title":"A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2026-01-20","conditions":"Dry Eye Disease (DED)","enrollment":25},{"nctId":"NCT03644667","phase":"PHASE2","title":"Tocilizumab in Cardiac Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-12-20","conditions":"Heart Transplant","enrollment":385},{"nctId":"NCT03656926","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":169},{"nctId":"NCT06790095","phase":"PHASE2","title":"TRACK-TBI Precision Medicine Part 3 - Option II","status":"ENROLLING_BY_INVITATION","sponsor":"University of California, San Francisco","startDate":"2026-02","conditions":"Traumatic Brain Injury","enrollment":26},{"nctId":"NCT07366801","phase":"PHASE2, PHASE3","title":"Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies","status":"RECRUITING","sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","startDate":"2025-09-03","conditions":"Acute Myeloid Leukemia, Relapsed, Acute Lymphoblastic Leukemia, High Risk, Acute Myeloid Leukemia, High Risk","enrollment":64},{"nctId":"NCT07368595","phase":"PHASE4","title":"Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","status":"NOT_YET_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2026-04-01","conditions":"Dry Eye Disease (DED)","enrollment":60},{"nctId":"NCT05136170","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2022-01-27","conditions":"Dry Eye Disease","enrollment":85},{"nctId":"NCT04795752","phase":"NA","title":"Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)","status":"COMPLETED","sponsor":"Sight Sciences, Inc.","startDate":"2021-04-28","conditions":"Dry Eye, Meibomian Gland Dysfunction","enrollment":345},{"nctId":"NCT07025811","phase":"PHASE4","title":"A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2025-07-09","conditions":"Dry Eye Disease","enrollment":350},{"nctId":"NCT03657342","phase":"PHASE3","title":"Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-03-26","conditions":"Bronchiolitis Obliterans, Chronic Rejection of Lung Transplant, Lung Transplant Rejection","enrollment":62},{"nctId":"NCT05579769","phase":"PHASE2","title":"Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2023-03-14","conditions":"Hematologic Malignancy, Myeloid Malignancy","enrollment":3},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06802055","phase":"PHASE2","title":"Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-01-25","conditions":"Aplastic Anaemia","enrollment":40},{"nctId":"NCT05998759","phase":"PHASE2","title":"Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2023-12-02","conditions":"Connective Tissue Diseases, Thrombocytopenia","enrollment":296},{"nctId":"NCT03025698","phase":"PHASE2","title":"A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-09-30","conditions":"Aplastic Anemia","enrollment":51},{"nctId":"NCT06504225","phase":"","title":"EVEROLD LONG TERM FOLLOW-UP","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2024-08-23","conditions":"Transplant; Complication, Failure","enrollment":260},{"nctId":"NCT04039347","phase":"PHASE3","title":"Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zambon SpA","startDate":"2020-03-12","conditions":"Bronchiolitis Obliterans, Obliterative Bronchiolitis, Bronchiolitis Obliterans Syndrome","enrollment":262},{"nctId":"NCT02034747","phase":"PHASE4","title":"A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Astellas Pharma Korea, Inc.","startDate":"2013-11-21","conditions":"Kidney Transplant","enrollment":150},{"nctId":"NCT02160054","phase":"","title":"Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2013-11-15","conditions":"the Maintenance Phase After Kidney Transplantation","enrollment":289},{"nctId":"NCT05743764","phase":"PHASE3","title":"HU007 in Patients with Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2023-03-23","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT04144413","phase":"PHASE3","title":"3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2019-05-31","conditions":"Dry Eye Disease With Severe Keratitis","enrollment":350},{"nctId":"NCT04129398","phase":"PHASE3","title":"MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-12-27","conditions":"Cytomegalovirus Infection, Cytomegalovirus Disease","enrollment":22},{"nctId":"NCT03840291","phase":"PHASE4","title":"Resolution of Thrombi in Left Atrial Appendage With Edoxaban","status":"COMPLETED","sponsor":"Keimyung University Dongsan Medical Center","startDate":"2019-05-19","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis","enrollment":36},{"nctId":"NCT00653276","phase":"PHASE1","title":"MD Ezetimibe Cyclosporine Interaction (0653-057)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2003-11","conditions":"Cholesterol","enrollment":13},{"nctId":"NCT03237936","phase":"PHASE4","title":"Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis","status":"COMPLETED","sponsor":"Santen SAS","startDate":"2017-03-28","conditions":"Keratitis","enrollment":17},{"nctId":"NCT00518375","phase":"PHASE4","title":"Study Comparing Graft Function in Renal Allograft Recepients Receiving Reduced or Standard Dose CsA With Sirolimus","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-04","conditions":"Kidney Transplantation","enrollment":250},{"nctId":"NCT04523142","phase":"PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2021-01-04","conditions":"Dry Eye Disease (DED)","enrollment":202},{"nctId":"NCT05323617","phase":"PHASE2","title":"Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy","status":"WITHDRAWN","sponsor":"Amgen","startDate":"2023-08-31","conditions":"Severe Aplastic Anemia (SAA)","enrollment":""},{"nctId":"NCT00471848","phase":"PHASE2","title":"Rabbit Antithymocyte Globulin (Thymoglobuline) With Ciclosporin for Patients With Acquired Aplastic Anaemia","status":"COMPLETED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2008-08","conditions":"Aplastic Anemia","enrollment":35},{"nctId":"NCT05293509","phase":"PHASE2","title":"Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-03-02","conditions":"Stem Cell Transplantation","enrollment":""},{"nctId":"NCT00905515","phase":"PHASE4","title":"Optima: Optimizing Prograf Therapy in Maintenance Allografts II","status":"COMPLETED","sponsor":"East Carolina University","startDate":"2003-08","conditions":"Kidney Transplantation","enrollment":63},{"nctId":"NCT06013436","phase":"","title":"AST Combined With 0.05% Cyclosporin Eye Drop Improve Corneal Nerve Density in Patients With SS Dry Eye","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2022-06-01","conditions":"Sjogren's Syndrome, Dry Eye, Ocular Surface Disease","enrollment":30},{"nctId":"NCT00045305","phase":"PHASE2","title":"Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-10-24","conditions":"Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms","enrollment":17},{"nctId":"NCT02936505","phase":"NA","title":"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2016-10-12","conditions":"Lung Transplantation, Allografts","enrollment":249},{"nctId":"NCT02745717","phase":"PHASE4","title":"The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia","status":"COMPLETED","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2016-01","conditions":"Severe Aplastic Anemia","enrollment":60},{"nctId":"NCT05771012","phase":"NA","title":"Topical Cyclosporin A 0.05% Eye Drops for Management of Symptomatic Acquired Punctal Stenosis. A Prospective, Controlled Clinical Study.","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2021-01-01","conditions":"Management of Punctal Stenosis","enrollment":42},{"nctId":"NCT04523129","phase":"PHASE3","title":"ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-12-05","conditions":"Dry Eye Disease","enrollment":834},{"nctId":"NCT02345850","phase":"PHASE3","title":"Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2015-08","conditions":"Acute Leukemia, Myelodysplasia","enrollment":346},{"nctId":"NCT00096460","phase":"PHASE2, PHASE3","title":"Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202)","status":"TERMINATED","sponsor":"Medical College of Wisconsin","startDate":"2004-08","conditions":"Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma","enrollment":30},{"nctId":"NCT03292809","phase":"PHASE2, PHASE3","title":"CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2017-10-19","conditions":"Dry Eye Disease","enrollment":328},{"nctId":"NCT01976390","phase":"NA","title":"Comparing Everolimus and Sirolimus in Renal Transplant Recipients","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2013-10-01","conditions":"Renal Failure","enrollment":60},{"nctId":"NCT00136903","phase":"PHASE2","title":"Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)","status":"COMPLETED","sponsor":"Mesoblast, Inc.","startDate":"2005-04-27","conditions":"Graft Vs Host Disease","enrollment":32},{"nctId":"NCT00412360","phase":"PHASE3","title":"Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2006-12","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia","enrollment":224},{"nctId":"NCT02328755","phase":"PHASE1, PHASE2","title":"Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2015-01","conditions":"Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT00789308","phase":"PHASE2","title":"Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2008-07-11","conditions":"Diabetes Mellitus, Type I","enrollment":24},{"nctId":"NCT03597139","phase":"PHASE2","title":"Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aurinia Pharmaceuticals Inc.","startDate":"2018-08-13","conditions":"Dry Eye","enrollment":100},{"nctId":"NCT03844932","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis","status":"TERMINATED","sponsor":"Sublimity Therapeutics Holdco Limited","startDate":"2019-01-24","conditions":"Colitis, Ulcerative","enrollment":235},{"nctId":"NCT04492878","phase":"PHASE4","title":"Efficacy and Safety of Ikervis Under Controlled Environmental Conditions Environment","status":"COMPLETED","sponsor":"Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA","startDate":"2020-02-04","conditions":"Dry Eye, Dry Eye Syndromes, Severe Keratitis","enrollment":25},{"nctId":"NCT02472054","phase":"PHASE1, PHASE2","title":"Treatment of Familiar Lymphohistiocytosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-06-29","conditions":"Hemophagocytic Lymphohistiocytosis (HLH)","enrollment":29},{"nctId":"NCT04775303","phase":"PHASE4","title":"A Clinical Trial to Evaluate the Clinical Efficacy of Cyclosporine 0.1% (Ikervis®) for Moderate to Severe Dry Eye Patients. (IKE-03-SWITCHING)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2020-09-25","conditions":"Moderate to Severe Dry Eye","enrollment":90},{"nctId":"NCT01820572","phase":"PHASE3","title":"A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-03-27","conditions":"Kidney Transplantation","enrollment":446},{"nctId":"NCT04637633","phase":"PHASE2, PHASE3","title":"Topical Cyclosporine-A for Management of Epiphora","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2020-08-15","conditions":"Epiphora","enrollment":12},{"nctId":"NCT02876679","phase":"PHASE2","title":"Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-04-06","conditions":"Graft vs Host Disease","enrollment":94},{"nctId":"NCT02755649","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-01-31","conditions":"Atopic Dermatitis","enrollment":325},{"nctId":"NCT00377962","phase":"PHASE4","title":"Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-12","conditions":"Disorder Related to Cardiac Transplantation","enrollment":282},{"nctId":"NCT03461575","phase":"PHASE3","title":"Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2018-01-22","conditions":"Dry Eye Syndrome","enrollment":209},{"nctId":"NCT04376970","phase":"PHASE4","title":"Treatment of Corneal Infiltrates Secondary to Epidemic Keratoconjunctivitis","status":"COMPLETED","sponsor":"Military Hospital of Tunis","startDate":"2017-04-01","conditions":"Adenoviral Keratoconjunctivitis","enrollment":51},{"nctId":"NCT04341038","phase":"PHASE3","title":"Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2020-04-01","conditions":"COVID-19, Lung Injury","enrollment":84},{"nctId":"NCT00553098","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-06","conditions":"Immunodeficiency Syndrome, Non-Cancer Diagnosis","enrollment":29},{"nctId":"NCT00040846","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2001-11","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":60},{"nctId":"NCT02617667","phase":"PHASE2","title":"CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2016-01","conditions":"Dry Eye Syndromes","enrollment":207},{"nctId":"NCT02167958","phase":"PHASE1","title":"Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source","status":"COMPLETED","sponsor":"Rafic Farah, MD","startDate":"2015-02-11","conditions":"Leukemia, MDS, Myelofibrosis","enrollment":28},{"nctId":"NCT02864706","phase":"PHASE4","title":"SCHEDULE Follow Up Visit 5-7 yr","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-01-18","conditions":"Heart Transplantation","enrollment":95},{"nctId":"NCT01817582","phase":"PHASE2","title":"Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-05-17","conditions":"Keratoconjunctivitis Sicca","enrollment":102},{"nctId":"NCT00827255","phase":"","title":"Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-01","conditions":"Dry Eye Disease","enrollment":35},{"nctId":"NCT02121847","phase":"PHASE4","title":"Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-04-03","conditions":"Dry Eye Syndromes","enrollment":40},{"nctId":"NCT03751332","phase":"PHASE4","title":"The Vienna Prograf and Endothelial Progenitor Cell Extension Study","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2008-03","conditions":"Immunosuppression, Renal Failure","enrollment":87},{"nctId":"NCT02328963","phase":"PHASE4","title":"Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-05-02","conditions":"Transplantation Infection, Cytomegalovirus Infection","enrollment":186},{"nctId":"NCT00565669","phase":"NA","title":"Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2007-10","conditions":"Dry Eye Syndrome","enrollment":20},{"nctId":"NCT01595984","phase":"PHASE3","title":"Comparison of Efficacy and Safety of Treatment With a Calcineurin Inhibitor (CNI)Versus a CNI-free Treatment in Renal Transplantation (CIME)","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2012-05-03","conditions":"Kidney Failure","enrollment":90},{"nctId":"NCT02013791","phase":"PHASE2","title":"Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease","status":"TERMINATED","sponsor":"Allergan","startDate":"2014-04-29","conditions":"Dry Eye Syndromes","enrollment":55},{"nctId":"NCT02917512","phase":"PHASE2","title":"Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome","status":"COMPLETED","sponsor":"Huons Co., Ltd.","startDate":"2016-03","conditions":"Dry Eye Syndrome","enrollment":114},{"nctId":"NCT01369082","phase":"","title":"Extended Follow-Up After Islet Transplantation in T1D","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-05","conditions":"Type 1 Diabetes (T1D), Islet Transplantation","enrollment":75},{"nctId":"NCT01825044","phase":"PHASE2","title":"Copenhagen Head Injury Ciclosporin (CHIC) Study","status":"COMPLETED","sponsor":"NeuroVive Pharmaceutical AB","startDate":"2013-04","conditions":"Traumatic Brain Injury","enrollment":16},{"nctId":"NCT01410448","phase":"PHASE3","title":"Everolimus in de Novo Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-11","conditions":"Kidney Transplantation","enrollment":383},{"nctId":"NCT02554981","phase":"PHASE4","title":"Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-07-21","conditions":"Dry Eye Syndromes","enrollment":51},{"nctId":"NCT01797315","phase":"PHASE4","title":"Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol","status":"TERMINATED","sponsor":"University Hospital of Berlin","startDate":"2007-03","conditions":"Renal Transplant Patients at High-risk for Skin Cancer","enrollment":40},{"nctId":"NCT01843348","phase":"PHASE3","title":"12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-27","conditions":"Kidney Transplantation, Renal Transplantation","enrollment":612},{"nctId":"NCT00698685","phase":"PHASE2","title":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation","status":"TERMINATED","sponsor":"University of Arizona","startDate":"2006-01-23","conditions":"Leukemia, Lymphoma, Hodgkin's Disease","enrollment":14},{"nctId":"NCT01064830","phase":"PHASE2","title":"Topical Cyclosporine Suspension for the Treatment of Brittle Nails","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2010-02","conditions":"Brittle Nail Syndrome","enrollment":21},{"nctId":"NCT00755040","phase":"PHASE3","title":"Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder","status":"COMPLETED","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2008-10","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":164},{"nctId":"NCT01509560","phase":"PHASE2","title":"PhaseII,Open-label,Pilot Study Evaluating the Safety+Efficacy of Certican ® in the Prevention of Chronic Graft-versus-host Disease+Late Pulmonary Complications After Allogeneic Hematopoietic Cell Transplantation Blood","status":"COMPLETED","sponsor":"Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH","startDate":"2011-11-01","conditions":"Condition After Allogenic Peripheral Stem Cell Transplantation (SCT)","enrollment":21},{"nctId":"NCT00637143","phase":"PHASE4","title":"Tacrolimus as Secondary Intervention vs. Continuation of Cyclosporine in Renal Transplant Patients With Chronic Renal Allograft Failure (CRAF)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"1999-04","conditions":"Renal Transplantation, Chronic Renal Allograft Failure","enrollment":107},{"nctId":"NCT00514514","phase":"PHASE3","title":"Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Calcineurin Inhibitor (CNI)-Free Regimen and a CNI-low Dose Regimen","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2007-07","conditions":"Kidney Transplantation","enrollment":802},{"nctId":"NCT02058875","phase":"PHASE4","title":"Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring","status":"WITHDRAWN","sponsor":"University of Saskatchewan","startDate":"2014-02","conditions":"Cardiovascular Disease, Cardiovascular Outcomes, Kidney Transplant Recipients","enrollment":""},{"nctId":"NCT01198782","phase":"PHASE4","title":"Evaluating Safety and Efficacy of FID 112903 Post Discontinuation of Long-term Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-09","conditions":"Dry Eye Syndrome","enrollment":48},{"nctId":"NCT00087581","phase":"PHASE4","title":"Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-06","conditions":"Kidney Transplantation","enrollment":720},{"nctId":"NCT02397213","phase":"PHASE2","title":"Ciclosporin to Protect Renal Function In Cardiac Surgery","status":"COMPLETED","sponsor":"Region Skane","startDate":"2015-04","conditions":"Acute Kidney Injury","enrollment":155},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT02799888","phase":"PHASE2","title":"Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2014-04","conditions":"Graft-versus-host Disease, Hematopoietic Stem Cell Transplantation","enrollment":40},{"nctId":"NCT02779114","phase":"PHASE3","title":"RETRO (REduction of Therapy in RA Patients in Ongoing Remission)","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2009-01","conditions":"Rheumatoid Arthritis","enrollment":318},{"nctId":"NCT02630563","phase":"PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2003-05","conditions":"Pediatric Liver Transplantation","enrollment":9},{"nctId":"NCT01901471","phase":"PHASE2","title":"Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock","status":"WITHDRAWN","sponsor":"Hospices Civils de Lyon","startDate":"2015-09","conditions":"Acute Myocardial Infarction","enrollment":""},{"nctId":"NCT02522312","phase":"","title":"A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients","status":"COMPLETED","sponsor":"Hazleton Eye Specialists","startDate":"2015-09","conditions":"Dry Eye Syndrome","enrollment":102},{"nctId":"NCT01530555","phase":"PHASE2","title":"Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2008-04","conditions":"Acquired Aplastic Anaemia","enrollment":35},{"nctId":"NCT01868360","phase":"PHASE1","title":"Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea","status":"TERMINATED","sponsor":"Balamurali Ambati","startDate":"2013-06","conditions":"Corneal Neovascularization","enrollment":2},{"nctId":"NCT01319773","phase":"PHASE1","title":"Study of Two Formulations of Cyclosporine Ophthalmic Emulsion in Healthy Volunteers and in Patients With Dry Eye","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Dry Eye Syndromes","enrollment":44},{"nctId":"NCT01467505","phase":"PHASE2","title":"An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients","status":"TERMINATED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2012-02","conditions":"Hepatitis C","enrollment":61},{"nctId":"NCT02130414","phase":"PHASE1","title":"PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects","status":"COMPLETED","sponsor":"Sigmoid Pharma","startDate":"2014-07","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Neoral® (Cyclosporine)","genericName":"Neoral® (Cyclosporine)","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclosporine inhibits T-cell activation by blocking calcineurin, a phosphatase required for IL-2 production and T-cell proliferation. Used for Organ transplant rejection prophylaxis (kidney, heart, liver, pancreas), Rheumatoid arthritis, Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}